Download biomedica product listThe new intact FGF23 ELISA was mentioned in the most recent Biocompare newsletter as a featured product. Check out the drug discovery and development newsletter to learn more.
FGF23 (intact) human ELISA
Features and Benefits
• RELIABLE and FULLY VALIDATED for plasma samples – according to ICH Q2
• SERUM, URINE and CC SUPERNATANT are compatible with this ELISA
• FAST ONE-STEP ELISA – only 3.5 h total incubation time
• PLASMA BASED STANDARDS and CONTROLS INCLUDED – for biologically reliable data
• CHARACTERIZED MONOCLONAL ANTIBODIES – high specificity and sensitivity guaranteed
• GOOD CORRELATION with existing ELISA methods
Why FGF23 ELISA from Biomedica?
√ Proprietary products – developed and manufactured in our European facilities
√ Excellent stability in all matrices after sample collection
√ CE registration in progress
Please click below for:
– Assay Validation Data
– Instruction For Use
– Biomedica FGF23 Info Leaflet
– Product Website
Related Product:
FGF23 (C-terminal) ELISA
Meet Biomedica Immunoassays at poster P95 “Detection of intact FGF23 using a novel well-characterized ELISA” to learn more about new FGF23 (intact) human ELISA and to discuss your research projects!
Useful links:
|
||
|
||
Göbel A. et al., J Bone Oncology, 2019; 16: 100237. Full publication.
SEMAPHORIN 4D is a soluble and membrane-bound protein
that plays important roles in physiologic processes such as vascular growth, tumor progression, and immune cell regulation.
Related literature:
The Role of Semaphorin 4D in Bone Remodeling and Cancer Metastasis.
Lontos K et al., Front Endocrinol, 2018; 9:322. Full publication.
A high-sensitivity enzyme immunoassay for the quantification of soluble human semaphoring 4D in plasma.
Laber A et al., Anal Biochem, 2019; 574:15-22. Full publication.
Did you know?
Soluble Semaphorin 4D can easily be quantified with the Biomedica SEMA4D ELISA
√ HIGHLY SPECIFIC – antibodies bind with high affinities to conformational epitopes in the sema domain
√ ACCURATE – successful validation according to FDA guidelines
√ RELIABLE – 7 human plasma based standards and 2 controls for biologically reliable data
√ LOW SAMPLE VOLUME – only 10 µl / well required
√ Plasma is the suitable matrix for reproducible quantification of sSEMA4D
May 11 – 14, 2019
Meet Biomedica Immunoassays at the ECTS Congress in Budapest – booth # 12 – to learn more about our soon to be launched new assay and to discuss your research projects!
In addition to having a booth, we will present the following posters:
-
Development and characterization of an extraction-free human CGRP sandwich ELISA
-
Novel ELISA for the detection of intact FGF23
Useful links:
Scientific Program
ECTS Homepage
May 9 – 11, 2019
Meet Biomedica Immunoassays at the Osteoporoseforum in St. Wolfgang to learn more about our soon to be launched new assay and to discuss your research projects!
- intact FGF23 ELISA
- C-terminal FGF23 ELISA
- bioactive Slcerostin ELISA
Useful links:
C-type natriuretic peptide (CNP), a small peptide hormone, plays a crucial role in linear growth. The growth plate is a major contributor to circulating CNP products in the immature skeleton. Its bio-inactive aminoterminal propeptide (NTproCNP) is easily measurable in plasma, and levels reflect the rate of CNP biosynthesis.
Plasma C-Type Natriuretic Peptide: Emerging Applications in Disorders of Skeletal Growth.
Espiner E et al.,Horm Res Paediatr,2019;7;90(6):345-357.
Did you know?
NT-proCNP can easily be quantified with the Biomedica 2nd generation NT-proCNP ELISA (cat.no. BI-20812)
√ HIGH SENSITIVITY – 0.7 pmol/l (= 3.49 pg/ml)
√ EASY – direct measurement – no concentration step
√ LOW SAMPLE VOLUME – only 20 µl / well required
√ ACCURATE – successful validation according to FDA guidelines
√ RELIABLE – 7 human plasma based standards and 2 controls for biologically reliable data
√ High cross-reactivity with rat NT-proCNP
Literature:
- Dynamic response of C-type natriuretic peptide and its aminoterminal propeptide (NTproCNP) to growth hormone treatment in children with short stature.
Olney RC et al.,Clin Endocrinol,2016;85(4):561-8. - Serum NT-proCNP levels increased after initiation of GH treatment in patients with achondroplasia/hypochondroplasia.
Kubota T et al.,Clin Endocrinol,2016;84(6):845-50. - Rats deficient C-type natriuretic peptide suffer from impaired skeletal growth without early death.
Fujii T et al.,PloS One,2018;13(3):e0194812.
WORLD CONGRESS ON OSTEOPOROSIS, OSTEOARTHRITIS AND MUSCULOSKELETAL DISEASES
April 4 – 7, 2019
Meet Biomedica Immunoassays at poster P676 “Novel ELISA Allows Accurate Quantification of Intact Fibroblast Growth Factor 23 (FGF23) in Serum and Plasma” to learn more about our soon to be launched new assay and to discuss your research projects!
Useful links:
Together with our partner Immundiagnostik from Bensheim, Germany, we presented Biomedica Immunoassays at the Osteologie congress in Frankfurt.
We proudly presented our soon to be launched ELISA for the quantitative measurement of intact FGF23 in a talk and generated a lot of interest in the test. The poster introducing our new bioactive Sclerostin ELISA, a test that specifically detects Sclerostin at its receptor binding site, was visited by many congress participants and was discussed a lot. Furthermore, a poster introducing our soluble Semaphorin 4D ELISA, a factor promoting skeletal metastasis, was presented the field of osteo-oncology.
We greatly enjoyed this interesting congress and look forward to next year’s Osteologie congress taking place in Salzburg, Austria!